NeuroPace Inc (NAS:NPCE)

Q2 2025 Neuropace Inc Earnings Call Transcript

Aug 12, 2025 / 08:30 PM GMT

Release Date Price: $9.13 (+2.70%)

Transcript 10-Q8-K

Key Points

Positve

NeuroPace Inc (NPCE) reported a record revenue of $23.5 million for Q2 2025, representing a 22% year-over-year growth.
The company achieved a total gross margin above 77% and an RNS gross margin above 80%, indicating strong financial performance.
NeuroPace Inc (NPCE) raised its full-year revenue guidance to a range of $94 million to $98 million, reflecting confidence in continued growth.
The Nautilus trial data showed promising results, with a median GTC seizure reduction signaling better than 80% reduction at both 18 and 24 months.
The company successfully refinanced its existing debt, providing enhanced financial flexibility and more favorable terms.

Negative

Operating expenses increased to $25 million in Q2 2025, partly due to one-time items related to executive transition.
The Nautilus trial did not meet its primary effectiveness endpoint due to variability in a small subset of patients.
Net loss for Q2 2025 was $8.7 million, compared to a net loss of $7.5 million in the same quarter of the previous year.
The company is in the process of winding down its distribution agreement with Dixie Medical, which may impact future revenue.
There is uncertainty regarding the FDA's response to the Nautilus trial data, and the potential requirement for additional clinical trials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NPCE.OQ - Neuropace Inc
Q2 2025 Neuropace Inc Earnings Call
Aug 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, greetings and welcome to the Neuropace Inc. 2nd quarter 2025 earnings call. At this time, all participants in the lesson mode. A brief question and answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please press star and 0 on your telephone keypad.

As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host Scott Shaper, head of investor relations at Neuropace Inc. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.